Utilizing AI and Social Media Analytics to Discover Unreported Adverse Side Effects of GLP-1 Receptor Agonists Used for Obesity Treatment
Files
Date
2025-01-07
Contributor
Advisor
Department
Instructor
Depositor
Speaker
Researcher
Consultant
Interviewer
Narrator
Transcriber
Annotator
Journal Title
Journal ISSN
Volume Title
Publisher
Volume
Number/Issue
Starting Page
5926
Ending Page
Alternative Title
Abstract
Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications used to treat diabetes and obesity, a market expected to grow exponentially to $133.5 billion USD by 2030. Using a named entity recognition model, our method successfully detected 15 potential ASEs of GLP-1 RAs, overlooked upon FDA approval. Our data-analytic approach revolutionizes the detection of unreported ASEs associated with newly deployed medications, leveraging cutting-edge AI-driven social media analytics. This ongoing research can increase the safety of new medications in the marketplace by unlocking the power of social media to support regulators and manufacturers in the rapid discovery of hidden ASE risks.
Description
Keywords
Digital Transformations of Business Operations, adverse side effect (ase), artificial intelligence (ai), glucagon-like peptide 1 receptor agonist (glp-1 ra), social media analytics
Citation
Extent
10
Format
Geographic Location
Time Period
Related To
Proceedings of the 58th Hawaii International Conference on System Sciences
Related To (URI)
Table of Contents
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Rights Holder
Local Contexts
Email libraryada-l@lists.hawaii.edu if you need this content in ADA-compliant format.